Compare PLBC & BLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PLBC | BLSM |
|---|---|---|
| Founded | 1980 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.2M | 483.4M |
| IPO Year | 2002 | 2026 |
| Metric | PLBC | BLSM |
|---|---|---|
| Price | $62.79 | $13.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $70.00 | $35.40 |
| AVG Volume (30 Days) | 44.5K | ★ 131.5K |
| Earning Date | 10-21-2026 | 11-19-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.30 | N/A |
| Revenue Next Year | $2.72 | N/A |
| P/E Ratio | $14.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.30 | $11.22 |
| 52 Week High | $64.95 | $27.99 |
| Indicator | PLBC | BLSM |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 42.76 |
| Support Level | $60.07 | $12.93 |
| Resistance Level | $63.60 | $17.53 |
| Average True Range (ATR) | 1.39 | 1.66 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 32.35 | 44.62 |
Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.